UCSD Business School’s Venture Fund Joins Texas Startup’s $16M Deal

Savara Pharma, Cystic Fibrosis, MRSA, Antibiotic, Vancomycin

courses in venture finance and capital management to source venture deals, conduct due diligence, and recommend investments. Any proposed investments by the Rady Venture Fund must be approved by one of two oversight committees comprised of professional VC investors.

“We cannot be the sole investor,” Rasochova says. “There has to be an independent investor to lead the round.” All of the deals the Rady fund has done so far were led by members of the Tech Coast Angels, with the Rady Venture Fund basically participating as an individual angel investor.

“It truly, truly gives the students the opportunity to learn hands-on how it works,” Rasochova says.

The investment in Savara also marks a departure from a vow Rasochova initially made to exclude investments in drug development companies (because of the time and costs involved) when the Rady Venture Fund was established. “To tell you the truth, I first ruled the investment out because of the drug development focus,” Rasochova explains in an e-mail this afternoon. “However, students were able to convince me and the investment committee and [we] received an approval to invest.”

While Rasochova cites several compelling reasons for making the investment, she says the Rady students assessing the deal had unexpectedly deep experience in the field. In particular, she says MBA student George Smith is a pharmaceutical scientist and an expert in respiratory diseases.

“Our students did a deep diligence and modeled various scenarios—at the end they made a convincing argument for an investment and why we should make it,” she writes. “So yes, they are a great company and we believe in their success. A secondary benefit is to provide students with real-world experience in drug development process (given that we are in San Diego), which is very valuable and do it under the reduced timeline, cost and lower risk scenario.”

Author: Bruce V. Bigelow

In Memoriam: Our dear friend Bruce V. Bigelow passed away on June 29, 2018. He was the editor of Xconomy San Diego from 2008 to 2018. Read more about his life and work here. Bruce Bigelow joined Xconomy from the business desk of the San Diego Union-Tribune. He was a member of the team of reporters who were awarded the 2006 Pulitzer Prize in National Reporting for uncovering bribes paid to San Diego Republican Rep. Randy “Duke” Cunningham in exchange for special legislation earmarks. He also shared a 2006 award for enterprise reporting from the Society of Business Editors and Writers for “In Harm’s Way,” an article about the extraordinary casualty rate among employees working in Iraq for San Diego’s Titan Corp. He has written extensively about the 2002 corporate accounting scandal at software goliath Peregrine Systems. He also was a Gerald Loeb Award finalist and National Headline Award winner for “The Toymaker,” a 14-part chronicle of a San Diego start-up company. He takes special satisfaction, though, that the series was included in the library for nonfiction narrative journalism at the Nieman Foundation for Journalism at Harvard University. Bigelow graduated from U.C. Berkeley in 1977 with a degree in English Literature and from the Columbia University Graduate School of Journalism in 1979. Before joining the Union-Tribune in 1990, he worked for the Associated Press in Los Angeles and The Kansas City Times.